About: The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 30 April 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована у квітні 2013 (uk) scientific article published on 30 April 2013 (en) مقالة علمية نشرت في 30 أبريل 2013 (ar)
publication date	wds:Q37248624-507BBB7C-99C2-4650-B6B0-C60ED13673C4
publication date	2013-04-30 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37248624-74C97343-AED5-4B11-9A85-1D0B805BF30C
language of work or name	English
cites work	wds:Q37248624-2C66BA0E-465E-4375-B416-2B2DE95B9FD8 wds:Q37248624-3898E447-8AB0-4099-AF00-0B9665EB4A60 wds:Q37248624-3F724680-4B8A-4660-896E-0ED1E5555CB7 wds:Q37248624-42A3466B-FA54-4B49-9572-B6F4113BC390 wds:Q37248624-47C3D412-F824-4710-AA5B-281A2ABE6929 wds:Q37248624-5051CE57-1E86-49CD-8F6D-269385C74F53 wds:Q37248624-590DC5C0-E8E7-4D62-9F22-5DB326BFA356 wds:Q37248624-5ED79A56-D053-42A8-AC71-045FE71F6CC3 wds:Q37248624-69E114C6-EAC8-4C68-9B51-20BB253C9DBF wds:Q37248624-75212CB0-306B-43E0-A539-31183147388D wds:Q37248624-7B319B6F-4965-4F2B-9B31-64090FBE44F5 wds:Q37248624-81E5B38E-660E-4A04-A55B-4D201FD8AC00 wds:Q37248624-89C0A3B4-F7DD-46B6-835E-547C24028EDA wds:Q37248624-903C818B-3D38-4560-AC97-4B2138800FB1 wds:Q37248624-B5A21326-EB15-4340-8E31-9FE71C155C85 wds:Q37248624-B8821158-03F4-42F6-9EFF-2E0708CB7766 wds:Q37248624-B8D5E4AF-52DC-43BF-8FA5-7A9FD107B85C wds:Q37248624-BB293115-A0D3-4F9E-A378-38F84D958097 wds:Q37248624-DB6B729D-5798-43B0-A867-1638081B244B wds:Q37248624-E2465B46-D2EB-4577-9BA4-E3B53F87C6CB wds:Q37248624-E350CCB0-74E6-438F-895E-860E1869F0F1 wds:Q37248624-E51A477A-2579-4937-85B1-88EB68472A8B wds:Q37248624-E9C6D289-69D8-4580-B13D-28CF38D4104D wds:Q37248624-F0C806D3-3938-4BC9-B8D0-FDBB94EAB772
cites work	Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Clinical guideline: management of gastroparesis Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Assessment of gastric emptying using a low fat meal: establishment of international control values GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis Influence of ghrelin on interdigestive gastrointestinal motility in humans Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life Ghrelin agonist TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type: covariate analysis of phase 2 data Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Epidemiology, mechanisms, and management of diabetic gastroparesis Development and content validity of a gastroparesis cardinal symptom index daily diary. The stimulation of antral motility by erythromycin is attenuated by hyperglycemia
author name string	wds:Q37248624-64E36945-2733-4DBE-BB18-A8E31DCC56C8
author name string	Steven A Smith
rdfs:label	The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (en) The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (ast) The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. (nl)
skos:prefLabel	The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (en) The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (ast) The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. (nl)
name	The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (en) The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (ast) The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. (nl)
author	wds:Q37248624-06B8D2D4-C8D6-4E09-96FC-40D9D2497F25 wds:Q37248624-08E2B4F0-5288-4A1C-8298-29873B2DEFB6 wds:Q37248624-4BA722CC-7FC4-401D-B159-F9C79A70B56D wds:Q37248624-72066246-D218-47A6-B8E1-F3E97773CE25 wds:Q37248624-8F0412CA-C61A-4696-B167-C241004ACA99 wds:Q37248624-A47AC950-820D-4AB5-811E-4C6067BB63CB wds:Q37248624-AD9D0B52-3718-427A-B109-BEB7D717933E wds:Q37248624-E7ED99BB-F305-4D2C-A2FC-E9D3D3B3A75A
author	Michael Camilleri Adrian Vella Michael D Ryks Alan R. Zinsmeister Duane Burton Andrea Shin Irene A Busciglio Deborah Rhoten
title	wds:Q37248624-929E018F-182D-4858-BC94-47F76B8656D5
title	The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus (en)
page(s)	wds:Q37248624-902CE488-6455-4C9D-8570-E2E28332213A
page(s)	1453-1459.e4

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software